Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis-Reference-Cited by-同舟云学术

Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis

Published:2023-08 Issue: Volume:76 Page:104770
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Seifer Gustavo,Arun Tarunya,Capela Carlos,Laureys Guy,Jones Eddie,Dominguez-Castro Patricia,Sanchez-de la Rosa Rainel,Hiltl Simone,Iaffaldano Pietro

Funder

Novartis Pharma AG

Novartis

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference26 articles.

1. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand;Anderson;Curr. Med. Res. Opin.,2008

2. Multiple sclerosis risk perception and acceptance for Brazilian patients;Bichuetti;Arq. Neuropsiquiatr.,2018

3. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019

4. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study;Buron;Neurology,2020

5. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy;Chalmer;J. Neurol.,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register;Multiple Sclerosis and Related Disorders;2024-07

2. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

3. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry;Journal of Neurology;2023-12-22

4. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?;Drugs;2023-09-19